Not available
Quote | Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)
Last: | $1.63 |
---|---|
Change Percent: | -1.81% |
Open: | $1.66 |
Close: | $1.66 |
High: | $1.66 |
Low: | $1.61 |
Volume: | 32,515 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)
BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European ...
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”...
Message Board Posts | Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CYCC News Article - Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces K | whytestocks | investorshangout | 01/05/2023 8:30:46 PM |
Sar Pas, | Cytobeliever | investorshub | 12/06/2022 9:37:42 PM |
So what do you have to say now? | Cytobeliever | investorshub | 11/22/2022 4:50:50 PM |
whytestocks: $CYCC News Article - Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 | whytestocks | investorshangout | 09/21/2022 2:45:48 PM |
znewcar1: CYCC 26% v10,2M c1.68 f9,994M H1.72 PMH1.99 flushed S1.42 then crawled out EOD | znewcar1 | investorshangout | 08/12/2022 2:02:07 AM |
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. Company Name:
CYCC Stock Symbol:
NASDAQ Market:
Cyclacel Pharmaceuticals Inc. Website:
BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European ...
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”...
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;...